- Report
- October 2024
- 90 Pages
Global
From €3500EUR$4,094USD£3,084GBP
- Report
- August 2024
- 78 Pages
Global
From €3500EUR$4,094USD£3,084GBP
- Report
- May 2023
- 113 Pages
Global
From €3500EUR$4,094USD£3,084GBP
- Drug Pipelines
- November 2018
- 39 Pages
Global
From €3205EUR$3,500USD£2,729GBP
- Report
- November 2021
- 747 Pages
Global
From €3663EUR$4,000USD£3,119GBP
- Report
- July 2024
- 233 Pages
Global
From €1702EUR$1,859USD£1,449GBP
€2432EUR$2,655USD£2,070GBP
- Report
- July 2023
- 382 Pages
Global
From €2289EUR$2,499USD£1,949GBP
€3269EUR$3,570USD£2,784GBP
- Book
- June 2019
- 496 Pages
- Book
- January 2016
- 472 Pages
- Book
- November 2022
- 300 Pages
- Book
- March 2022
- 896 Pages
- Book
- September 2021
- 432 Pages
- Book
- February 2021
- 544 Pages

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more